BIXINK THERAPEUTICS
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the construction and convergence of technology that encompasses the times.
BIXINK THERAPEUTICS
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Font Awesome Mobile Non Scaleable Content Nginx Amazon Organization Schema Person Schema
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-12-07 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 15 M USD |
| 2020-05-05 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 9 M USD |
More informations about "BIXINK Therapeutics"
BIXINK
May 24, 2020 BIXINK, Breast cancer adjuvant treatment 'Nerlynx' has entered into Big 5 General Hospital 0 0 21 Sep 2022 ... 0 0 20 Jul 2022 Views 4733 Bixink Therapeutics signs deals to …See details»
빅씽크 l BIXINK
빅씽크, 美 청소년 우울증 디지털 치료제 국내 독점 계약 체결See details»
BIXINK Therapeutics - Crunchbase Investor Profile & Investments
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the …See details»
BIXINK Therapeutics investment portfolio - PitchBook
BIXINK Therapeutics General Information Company Description. Founded in 2016, BIXINK Therapeutics is a venture capital investment firm based in Seoul, South Korea. The firm seeks …See details»
BIXINK Therapeutics - Investments, Portfolio & Company Exits
BIXINK Therapeutics has had . obfuscated. obfuscated. exit, which was Limbix. Which industries has this organization had the most exits in? Show . Limbix Limbix is a prescription digital …See details»
Subsidiaries of KPS - kpscorp.co.kr
BIXINK. BIXINK THERAPEUTICS is a new biopharmaceutical company aiming to develop a new treatment paradigm with creativity and innovation. The global market for therapeutic agents, …See details»
Bixink Therapeutics signs deals to expand DTx pipelines
May 24, 2022 Bixink Therapeutics is accelerating efforts to build a diverse digital therapeutics (DTx) portfolio by clinching a series of DTx deals. Bixink is a biotech subsidiary of KPS Corp. …See details»
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive ...
Apr 30, 2020 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs …See details»
BIXINK
BIXINKSee details»
Bixink Therapeutics - VentureRadar
Bixink Therapeutics is a biotech subsidiary of KPS Corp that focuses on building a diverse digital therapeutics (DTx) portfolio. The company has signed several DTx deals, including an …See details»
MEDIA - BIXINK
Jul 20, 2022 Bixink Therapeutics signs deals to expand DTx pipelines Halimriadi Richar 24 May 2022 Views 5118 0; 12; Nerlynx in HER2-positive Early Breast Cancer, helping to overcome …See details»
Boryung and Bixink to co-market Nerlynx for HER2-positive breast …
Apr 4, 2024 Bixink Therapeutics has applied for health insurance benefits but has failed to get them. In the first year of its launch, Nerlynx reportedly generated 6 billion won in annual sales. …See details»
How will Nerlynx affect HER2-positive early breast cancer …
Jul 20, 2022 In 2021, Korean biotech firm Bixink Therapeutics introduced Nerlynx Tab. (neratinib), a HER2 inhibiting breast cancer treatment developed by Puma Biotechnology and …See details»
BIXINK
Bixink Therapeutics, a start-up biopharmaceutical company that creates new treatment paradigms through creativity and innovation, is growing through strengthening its internal compliance …See details»
MEDI:GATE NEWS 빅씽크, 유방암 연장보조요법 치료제 너링스정 …
Sep 21, 2022 빅씽크테라퓨틱스(BIXINK THERAPEUTICS)는 유방암 신약 '너링스(Nerlynx)'가 2월 출시 후 서울대병원과 서울아산병원, 삼성서울병원, 세브란스병원, 서울성모병원 등 빅5 …See details»
Bixink Therapeutics - VentureRadar
Similar Companies: InStride Health USA Private InStride Health specializes in evidence-based outpatient treatment for pediatric anxiety and OCD. They offer a comprehensive approach that …See details»
Bixink Therapeutics and Professional Dietetics enter into …
Aug 5, 2021 Bixink Therapeutics and Professional Dietetics enter into partnership for the MUCOSAMIN® range, onco-supportive care, whereby Bixink will hold the exclusive …See details»
Will Nerlynx satisfy unmet demand for early breast cancer in Korea ...
Jan 20, 2022 Bixink Therapeutics emphasized that Nerlynx is the nation’s first and only extended adjuvant therapy for HER2 positive early breast cancer. Park explained that the ultimate goal …See details»
2025-04-28 Acquisition of US Biopharma Company SpringWorks …
6 days ago SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only …See details»
BIXINK
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer SymposiumSee details»